{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-070732","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.638887+00:00","generated_at":"2026-06-18T02:19:12.830916+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Royalty Pharma receives $475M milestone from Pfizer on Zavzpret approval, raises 2023 guidance","bullets":["Received $475M accelerated milestone payment from Pfizer following FDA approval of Zavzpret (zavegepant) for acute migraine.","Raised full-year 2023 Adjusted Cash Receipts guidance to $2,850M-$2,950M from prior $2,375M-$2,475M.","Royalty Pharma will now earn royalties on net sales of both Nurtec ODT and Zavzpret.","CEO Pablo Legorreta noted the milestone provides additional capital for redeployment to create long-term shareholder value.","Guidance excludes contributions from future transactions and assumes no major unforeseen adverse events."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-070732","json":"https://secwatch.observer/filing/0001193125-23-070732.json","markdown":"https://secwatch.observer/filing/0001193125-23-070732.md","text":"https://secwatch.observer/filing/0001193125-23-070732.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312523070732/0001193125-23-070732-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312523070732/d398207d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T02:19:12.830916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}